Skip to content

Short-cycle intermittent HAART maintains undetectable viral load, but does not increase CD4 counts

Genotype testing before treatment may identify patients susceptible to protease inhibitor resistance

Atazanavir significantly reduces lipids 12 weeks after switching from nelfinavir

Delaying HAART until CD4 counts are below 200 cells/mm3 results in poorer outcome

Canadian study warns that inability to access addiction treatment is associated with syringe sharing

Symptoms just as good as CD4 counts for identifying who needs treatment in South Africa

Limited role in care for total lymphocyte count?

Stopping nevirapine five days prior to nucleosides may avoid resistance

Symptoms versus laboratory monitoring as criteria for starting treatment